Key Insights

Highlights

Treatment Research

1 treatments under study, led by Neoadjuvant Therapy Of Encorafenib Plus Cetuximab N01 And Mfolfox6

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT07789210Phase 2Recruiting

A Single-Arm, Phase II, Multicenter Clinical Study of Neoadjuvant Encorafenib Plus Cetuximab N01 and mFOLFOX6 in Patients With Locally Advanced BRAF V600E-Mutant Colorectal Cancer With or Without Resectable Metastases

Showing all 1 trials

Research Network

Common Treatments

  • Neoadjuvant Therapy Of Encorafenib Plus Cetuximab N01 And Mfolfox61

Active Sponsors

  • Zhejiang University1

Top Investigators

  • Kefeng Ding1

    Second Affiliated Hospital, Zhejiang University, School of Medicine

Related Conditions

  • Braf V600e Mutation Positive1
  • Colorectal Cancer1
  • Cetuximab N011

Activity Timeline